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INTRODUCTION
Craniosynostosis, the premature fusion
of one or more cranial sutures, is a rela-
tively common malformation with an inci-
dence of 1:2.500 births. Apert syndrome
(AS [MIM 101200]) is one of the most se-
vere forms of craniosynostosis, accounting
for 4.5% of all cases in different popula-
tions (1). AS also is characterized by mid-
facial hypoplasia and severe symmetric
bony and cutaneous syndactyly of the
hands and feet. Although the coronal su-
ture is closed at birth, the squamosal and
the lambdoid suture are opened and the
anterolateral fontanelles are much en-
larged because of a wide midline calvarial
defect. Many other anomalies are associ-
ated with AS, such as central nervous sys-
tem, cardiovascular, urogenital, and der-
matologic abnormalities (2–5). Inheritance
is autosomal dominant and most cases
represent new mutations which are exclu-
sively of paternal origin (6). Early correc-
tive cranial surgical intervention is needed
to allow proper brain and skull growth.
As a result of continuous bone healing
defect, several surgeries are usually neces-
sary during childhood and puberty.
Two activating missense mutations on
the fibroblast growth factor 2 receptor
(FGFR2) cause the great majority of AS
cases: p.Ser252Trp (c.755C > G) and
p.Pro253Arg (c.758C > G) (7). They are
located in the linker region between im-
munoglobulin-like loops II and III of the
FGFR2: the former is present in about
two thirds of the patients and is associ-
ated with a more severe craniofacial phe-
notype and the latter is found in the re-
maining one third of the patients and is
associated with a more severe syndactyly
(4). These mutations are present in mes-
enchymal “FGFR2c” and epithelial
“FGFR2b” splice isoforms and they both
involve substitutions of bulky side-chain
amino acids, which can alter the relative
orientation of the ligand-binding sites of
this receptor. Either of these changes lead
to enhanced FGFR2 ligand binding affin-
ity and decreased specificity (8–10).
FGFR activation by FGFs (fibroblast
growth factors) can induce several differ-
ent cell processes, such as differentiation,
proliferation, migration, and apoptosis by
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Apert syndrome (AS), a severe form of craniosynostosis, is caused by dominant gain-of-function mutations in FGFR2. Because
the periosteum contribution to AS cranial pathophysiology is unknown, we tested the osteogenic potential of AS periosteal cells
(p.Ser252Trp mutation) and observed that these cells are more committed toward the osteoblast lineage. To delineate the gene
expression profile involved in this abnormal behavior, we performed a global gene expression analysis of coronal suture periosteal
cells from seven AS patients (p.Ser252Trp), and matched controls. We identified 263 genes with significantly altered expression in
AS samples (118 upregulated, 145 downregulated; SNR ≥ |0.4|, P ≤ 0.05). Several upregulated genes are involved in positive reg-
ulation of cell proliferation and nucleotide metabolism, whereas several downregulated genes are involved in inhibition of cell
proliferation, gene expression regulation, cell adhesion, and extracellular matrix organization, and in PIK3-MAPK cascades. AS ex-
pression profile was confirmed through real-time PCR of a selected set of genes using RNAs from AS and control cells as well as
from control cells treated with high FGF2 concentration, and through the analysis of genes involved in FGF-FGFR signaling. Our
results allowed us to: (a) suggest that AS periosteal cells present enhanced osteogenic potential, (b) unravel a specific gene ex-
pression signature characteristic of AS periosteal cells which may be associated with their osteogenic commitment, (c) identify
a set of novel genes involved in the pathophysiology of AS or other craniosynostotic conditions, and (d) suggest for the first time
that the periosteum might be involved in the pathophysiology of AS.
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activating a variety of intracellular path-
ways, including MAPK (mitogen-activating
protein kinase), PI3K (Phosphoinositide-3
kinase), PKC (protein kinase C), and STAT
(signal transducers and activator of tran-
scription) pathways (5). Cellular context
and cell nature are important factors that
determine the cellular consequences of re-
ceptor stimulation. Normal FGFR1-3 sig-
naling also is crucial in the processes of
cell growth and differentiation at the cra-
nial sutural margins and alterations in
the molecular pathways or in the timing
of the activation events can lead to the
premature fusion of these margins.
Most of the studies on the cellular con-
sequences of AS mutant FGFR2 activation
have been focused on calvarial osteoblasts,
both in vitro and in vivo (11–17). Several
lines of evidence indicate that the perios-
teum plays an important role in cranial
bone regeneration because removal of
this tissue decreases vascularization and
calcification of cranial defects in animal
models (18,19). However, little or no in-
formation about the periosteal cells’ role
in the pathophysiology of AS is available.
We have postulated that the AS cranial
periosteal cells may behave abnormally
and contribute to enhanced suture ossifi-
cation, and therefore we decided in the
present work to test this hypothesis.
A transcriptional gene expression signa-
ture in periosteal AS cells has been previ-
ously reported based on the analysis of
only one patient harboring the p.Pro253Arg
mutation and two controls (20). Therefore,
the confirmation of these results with a
larger number of patients and controls is
clearly warranted. Nonetheless, given that
one of the most considerable challenges in
the field of molecular medicine is to dissect
the mechanisms of isolated cases of genetic
diseases, including syndromic craniosynos-
tosis, the identification of gene expression
profiles associated with specific Mendelian
disorders could become a powerful tool to
unravel the underlying causes of this group
of diseases.
Thus, the present study aimed to eval-
uate if p.Ser252Trp FGFR2 mutant pe-
riosteal cells present a greater commit-
ment toward osteogenic differentiation,
which could contribute to the patho-
physiology of AS, and to address if these
cells present a transcriptional signature
that would be involved in the molecular
mechanisms of this syndrome.
SUBJECTS, MATERIAL, AND METHODS
Subjects
During corrective surgery, overlying
periosteum from the coronal suture re-
gion of seven AS patients (three males
and four females aged from three
months to 14 years) was meticulously
dissected away from surrounding tissues
to isolate intact periosteal flaps. Control
periosteum was obtained using the same
procedure from the coronal suture region
of seven subjects (three males and four
females aged from 11 months to 13 years)
with no evidence of bone disease during
craniotomy for removal of brain tumors.
The project was approved by the local
ethical committee and appropriate in-
formed consent was obtained from each
subject or their legal guardians.
The presence of the p.Ser252Trp mu-
tation was confirmed by direct DNA
sequencing.
Cell Culture and RNA Isolation
Primary periosteal fibroblast cells
derived from the periosteal flaps were
grown in fibroblast growth medium (80
percent DMEM, 20 percent fetal bovine
serum [FSB] and 2 mmol/L l-glutamine,
penicillin, and streptomycin), in a hu-
midified incubator at 37ºC and five per-
cent CO2. Cells were passaged at near
confluence with trypsin-EDTA. All tests
were performed between the sixth and
the eighth subculture.
Although the primary periosteal fibrob-
last cells appeared as a homogeneous
population of fibroblastoid cells, to fur-
ther attest that the surgical isolation of
periosteum as well as the cell culture ex-
pansion procedure were leading to a ho-
mogeneous cell sample, immunocyto-
chemistry experiments were performed in
two control cell lineages using antibodies
specific for mesenchymal cells (SH2 and
SH3) and epithelial cells (Cytokeratin 18
and Integrin B1). It was observed that
these cells stained homogeneously for the
mesenchymal cells markers but not for
the epithelial ones. As a positive control,
cultured skin fibroblasts from an unaf-
fected subject were used, which stained
homogeneously for the epithelial cells
markers but not for the mesenchymal
cells markers.
Total RNA was isolated from confluent
control and AS cells using TRIZOL
reagent (Gibco BRL Gaithersburg, MD,
USA) and purified with RNeasy mini-
columns (Qiagen Valencia, CA, USA).
RNA quality and concentration were ac-
cessed respectively by 1.5 percent agarose
gel electrophoresis and spectrophotometry.
FGFR2 Expression Analysis
To verify the presence of the FGFR2 in
AS and control periosteal cells we per-
formed RT-PCR, Western blot, and im-
munocytochemical experiments.
Expression Analysis of FGFR2 by RT-PCR
One step RT-PCR (Invitrogen Carlsbad,
CA, USA) was performed with 2 μg of
total RNA samples from five AS patients
and four control subjects and specific
primer pairs for each of the two major
isoforms of FGFR2 (FGFR2b and
FGFR2c). The same forward primer
(FGFR2-6F: 5′-agtgtggtcccatctgacaag-3′)
was combined with a reverse primer spe-
cific for either the FGFR2b (FGFR2b-9R:
5′-ggcctgccctatataattgga-3′) or FGFR2c
(FGFR2c-10R: 5′-atagaattacccgccaagcac-3′)
isoform. A total of 35 cycles of amplifica-
tion were performed. Reaction products
were resolved alongside a 100-bp ladder
on 1.5 percent agarose gel.
Western Blot and
Immunocytochemical Experiments
Cell lysates from three AS patients and
from three control subjects were pre-
pared in RIPA Buffer (5 mM Tris-HCl
pH7.4, 150 mM NaCl, 1 mM EDTA, 0.1
percent SDS, 0.5 percent sodium deoxy-
cholate, one percent Nonidet 40) and 500
μg of protein were subject to Western
blot analysis using a dilution of 1:250 of
primary antibody BEH (H-80: sc-20734,
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Santa Cruz Biotechnology Santa Cruz,
CA, USA), and 1:1000 of anti-rabbit alka-
line-phosphatase conjugated secondary
antibody. For the immunocytochemical
experiments, cells were treated with
paraformaldehyde (four percent during
30 min) and labeled with 1:100 of the
first antibody BEH and 1:100 of the sec-
ond anti-rabbit-Cy3 antibody. As posi-
tive control we used the murine adeno-
cortical Y1 cells (kindly provided by Dr.
Hugo Armelin). Control staining with-
out primary antibody was used as nega-
tive control.
In Vitro Osteogenic Differentiation
To induce osteogenic differentiation,
periosteal fibroblasts from two AS pa-
tients and two controls were cultured for
three weeks in DMEM ten percent FBS,
0.1 mM dexamethasone, 50 mM ascor-
bate-2-phosphate, 10 mM β-glycerophos-
phate, 0.1 percent antibiotic, with media
changes every three to four days. After
21 days, calcified matrix production was
analyzed by von Kossa staining as previ-
ously described (21).
Microarray Assays, Normalization,
and Statistical Analyses
Gene expression experiments were per-
formed using CodeLink bioarray systems
(GE Healthcare Buckinghamshire, UK) ac-
cording to manufacturer’s protocols. In
brief, first-strand cDNA was produced
using 2 μg of total RNA from each sample,
Superscript II reverse transcriptase and a
T7-poly-dT primer. Second-strand cDNA
was produced using RNase H and E. coli
DNA polymerase I. Double-stranded
cDNA was purified on a QIAquick col-
umn (Qiagen) and biotin-labeled cRNA
targets were generated by an in vitro tran-
scription reaction using T7 RNA poly-
merase and biotin-11-UTP (Perkin Elmer-
Foster City, CA, USA). Fragmented cRNA
from each sample was hybridized to
CodeLink microarrays containing approxi-
mately 20,000 (20K, five samples) or 55,000
(55K, nine samples) 30-mer probes
overnight at 37°C in a shaking incubator
at 300 rpm. After post-hybridization
washes, hybridized targets were revealed
by incubating the arrays with a Cy5-Strep-
tavidin conjugate. The reagents used in
the synthesis and fragmentation of cRNA
were provided in the CodeLink expression
assay kit (GE Healthcare). Signal of the
Cy5-dye from hybridized targets were
detected with a GenePix 4000B scanner
(Axon Instruments Foster City, CA, USA).
CodeLink Expression Analysis software
(GE Healthcare) was used to obtain back-
ground-subtracted spot intensities from
microarray images. A set of 19,683 cDNA
probes present in both the 20K and 55K
arrays were analyzed. From these, only
9,543 probes that had valid measurements
(i.e. were detected above the average array
background as determined by a set of neg-
ative controls represented in the CodeLink
arrays) in at least six out of seven samples
from AS or control samples were further
analyzed. To make experiments compara-
ble, intensity data from different hy-
bridizations were normalized by two dif-
ferent methods: (i) trimmed mean
excluding the 20 percent of spots with
higher and lower intensities, or (ii)
Lowess, local weighted scatter-plot
smoothing (22). Data adjusted by Lowess
to a reference file resulted in lower coeffi-
cient of variation values across all samples
and were used in further analyses. To
identify gene expression signatures of AS,
a Signal-to-Noise Ratio (SNR) metric (23)
was used to compare the expression inten-
sity data from AS samples to control sam-
ples. The SNR parameter essentially is a
measure of signal strength relative to
background noise. The distance between
the two groups was measured by a signal-
(expression intensity) to-noise (variation)
ratio. The signal-to-noise comparison
gives an indication of the level of separa-
tion for the means of the two distributions
defining the gene intensities of the two
groups, and it was calculated as SNR =
√(μ1 – μ2)
2 / (SD1 + SD2), where μ1 and μ2
are the mean intensities of Apert and con-
trol groups, respectively, and SD1 and SD2
the corresponding standard deviations.
For each gene, higher absolute SNR values
indicate a higher difference of expression
between AS and control samples with a
lower dispersion within each group. A
cutoff SNR ≥ |0.4| was used to select dif-
ferentially expressed genes. Statistical sig-
nificance of the differential expression (P
values) was ascertained by bootstrap re-
sampling, i.e. by re-calculating SNR values
following 10,000 random permutations of
sample labels and computing the fre-
quency at which each SNR value mea-
sured in the original set was observed in
the randomly permuted data (24). The ro-
bustness of identified AS gene expression
signature was evaluated by sample leave-
one-out cross-validation (25). Essentially,
one sample is removed and a new set of
significantly altered genes is determined
using the remainder samples. This proce-
dure was repeated for each one of the 14
AS/control samples and the frequency at
which each gene appears in the various
“leave-one-out” datasets at a given signifi-
cance (P ≤ 0.05) was annotated.
The reproducibility of the gene expres-
sion measurements was assessed by gen-
erating two independent replicate target
preparations for each of two AS patients
and one control and hybridization of the
replicates to separate 55K or 20K microar-
rays, the two types of microarray plat-
forms used in our gene expression experi-
ments. Pair-wise comparison using the
Pearson correlation was applied to com-
pare the intensity values from the 19,683
probes common to both CodeLink plat-
forms. Intensity values from the probes
common to both microarray platforms
were highly correlated between sample
replicates (average Pearson correlation =
0.95 ± 0.01) among the three sets of hy-
bridizations. This result confirms that in-
tensity measurements obtained in the dif-
ferent platforms can be compared without
any significant loss in accuracy. In addi-
tion, the average correlation measured in
pairwise analyses with data from all 14
different samples was 0.83 ± 0.07.
Reverse Transcription Reactions and
Quantitative Real-time PCR
Complementary DNA (cDNA) was pro-
duced from four μg of total RNA using Su-
perscript II reverse transcription kit (Invitro-
gen). Quantitative real-time PCR (qRT-PCR)
was performed using approximately 200 ng
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of cDNA and SYBR Green PCR master mix
in an ABI Prism 7100 system (Applied
Biosystems Foster City, CA, USA). The PCR
conditions were: 94°C for 15 s, 58°C for 30 s,
and 72°C for 30 s for 40 cycles.
Samples from four AS and four controls
were run in triplicates, and the threshold
suggested by the instrument software
was used to calculate Ct. To normalize the
readings we used Ct values from HPRT1
(Hypoxanthine phosphoribosyltransferase 1)
and SDHA (succinate dehydrogenase com-
plex, subunit A) as internal controls in each
run, obtaining a delta Ct value for each
tested gene (STMN1, SPAG5, RRM2, HIP2,
CENPN, EEF1B2). Primers used in this
study are summarized in Table 1 as sup-
plementary information.
Exogenous FGF2 Treatment
Control periosteal fibroblasts were
grown to about 80 percent confluence
in six 25 cm2 cell culture bottles as de-
scribed. Cells were washed with PBS
and then were serum starved for 24 h
in DMEM not supplemented with FBS.
After this period, control cells (three bot-
tles) were treated with DMEM contain-
ing 0.5 percent FBS and experimental
cells (three bottles) were treated with
DMEM 0.5 percent FBS and recombinant
bovine FGF2 (provided by Dr. Hugo
Armelin) to a final concentration of 36
ng/mL (or 2000 pM – at this high con-
centration phosphorylation of both wild
type and mutant FGFR2c was similar, as
observed by 9). Control and experimen-
tal cells were harvested at three, six, and
24 h after addition of FGF2, and had its
total RNA isolated and purified as de-
scribed. cDNA was obtained by reverse
transcription of two μg of total RNA
using Superscript II (Invitrogen). qRT-
PCR was used to measure expression
levels of STMN1, SPAG5, RRM2, HIP2,
CENPN, EEF1B2 after FGF2 stimulation.
RESULTS
Morphology and FGFR2 Expression
Analysis in Periosteal Cells
Cultured coronal suture periosteal
cells from wild type controls and AS pa-
tients appeared microscopically to be a
homogeneous population of adherent
fibroblast-like cells, which exhibited nei-
ther morphology alteration nor signifi-
cant cell death after several passages.
As expected for a homogeneous cellular
population of periosteal cells with mes-
enchymal origin, we observed only the
expression of the FGFR2c isoform in con-
trol and AS periosteal cells, with no ap-
parent difference between these two, as
determined by RT-PCR. FGFR2 protein
also was detected in similar amounts both
in control and AS cells (data not shown).
Differentiation of Periosteal Fibroblasts
to the Osteoblast Cell Lineage
To address if AS periosteal cells pres-
ent a greater osteogenic potential, control
and AS cells (Figure 1A) were treated
with osteogenic induction medium. We
found that the potentiality to differenti-
ate to osteogenic lineage varied signifi-
cantly between control and AS cellular
Table 1. Sequence of the primers used in the quantitative Real Time PCR experiments.
Gene Forward sequence Reverse sequence
CENPN TCAGTGATGCTGCCCTGTTAGA AGTGATGCTGCCCTGTTAGACA
STMN1 GGCAGGACTTTCCTTATCCCA GGCAGGACTTTCCTTATCCCA
SPAG5 GAGTTCAAGGAGGTGCTGAAGA TGTCTGGAGGTCCTGCTATTTC
RMM2 CTTTGTCATCTTCCCCATCGAG TGCTGAATGTCCTTGGAGAGGT
HIP2 GAGTTCAAGGAGGTGCTGAAGA TGTCTGGAGGTCCTGCTATTTC
EEF1B2 TTCGGAGACCTGAAAAGCCCT CGGCTTCAAATACTGCCACATC
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG
Figure 1. (A) Morphology of undifferentiated AS periosteal cells. (B and C) Osteogenic dif-
ferentiation of periosteal cells after 21 days of culture in osteogenic medium. Secretion of
a calcified extracellular matrix was clearly observed. (D) Control cells after 21 days of os-
teogenic induction without signals of osteogenic differentiation (mineralized matrix are
absent). Differentiation was accessed by von Kossa staining.
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populations. Four days after the begin-
ning of treatment, an osteoblast-like phe-
notype was observed in AS cells, while
control cells maintained the fibroblast-
like morphology. After 21 days of treat-
ment, we observed several areas positive
for calcium staining by the von Kossa re-
action in AS cells (Figure 1 B and C), but
not in control cells (Figure 1 D).
Differential Gene Expression
To verify whether there is an expres-
sion signature associated with the pres-
ence of the p.Ser252Trp mutation, which
could explain the altered mutant cell be-
havior, we performed genome-wide ex-
pression analysis with RNA samples from
seven AS patients and seven gender- and
age-matched controls using either 55K
or 20K microarray platforms. We found
9,543 transcripts (out of 19,683 tran-
scripts under analysis) that were ex-
pressed in at least six out of seven sam-
ples from AS or control subjects. The av-
erage expression levels of 263 genes were
found to be significantly altered in AS
samples when compared with normal
subjects (118 genes upregulated and 145
downregulated) (Figure 2, Table 2 – 
supplementary information), using as
thresholds an absolute SNR ≥ |0.4| and
P ≤ 0.05 (see Methods section for details).
Submitting the 263 differentially ex-
pressed genes to the KEGG Pathway
Database, the Gene Ontology Database
(AmiGO), and the NCBI (Gene) data-
base, we found that 186 of them have a
known or inferred function. Among
them, we found 98 genes that could be
grouped in the following functional cate-
gories: regulation of cell proliferation (36
genes; among them, 28 and eight genes
are involved in positive and negative
regulation of cell proliferation, respec-
tively), nucleotide metabolism (ten genes),
regulation of gene expression (32 genes),
apoptosis (17 genes), cell adhesion (13),
extracellular matrix component or bio-
genesis (seven genes), and MAPK path-
ways (16 genes) (Table 3). Some genes
belong to more than one functional cate-
gory. These categories were selected be-
cause they contain the largest numbers
of genes, and because genes with related
biological functions already were associ-
ated to FGFR2 signaling.
From this analysis, we observed that
the most abundant classes of transcripts
were those associated with regulation of
cell proliferation and regulation of gene
expression. In addition, among the 98
genes functionally classified, 45 were
upregulated while 53 were downregu-
lated in AS cells. Among the upregulated
genes, the majority belong to positive
regulation of cell proliferation and nu-
cleotide metabolism categories (29/45
genes or ~64.4%) (Table 3).
Figure 2. Hierarchical clustering of a 263 gene expression signature of AS samples relative to normal control samples. Individual genes
are represented in lines and different samples are represented in rows. Expression level of each gene is represented by the number of
standard deviations above (red) or below (blue) the average value for that gene across all samples. Color intensity is proportional to the
number of standard deviations in the range –1.5 to 1.5, as indicated by the color-coded bar at the bottom of the figure.
R E S E A R C H  A R T I C L E
M O L  M E D  1 3 ( 7 - 8 ) 4 2 2 - 4 4 2 ,  J U L Y - A U G U S T  2 0 0 7  |  F A N G A N I E L L O  E T  A L .  |  4 2 7
Table 2. 263 transcripts differentially expressed in AS cells as compared with control samples. Transcripts are ordered by their Apert-to-
control ratios (Log 2).
Apert-to- x-fold 
Gene control down-
(Official Accession P Ratio regulated 
Symbol) Gene name number SNRa value (Log2) in Apert
DKFZp434B eEF1A2 binding protein NM_178275.3 –0.86 0.010 –2.66 6.31
1231b
TNNT1c troponin T type 1 (skeletal, slow) F36108.1 –0.662 0.017 –2.45 5.46
TNXBb tenascin XB NM_032470.2 –0.769 0.015 –2.32 4.98
CYHR1b cysteine/histidine-rich 1 AB007965.1 –1.013 0.010 –2.21 4.62
RTN4RL1b reticulon 4 receptor-like 1 AL834409.1 –0.812 0.023 –1.83 3.57
CCRL1 chemokine (C-C motif) receptor-like 1 NM_016557.2 –0.65 0.035 –1.77 3.42
NISC_np07a NISC_np07a06y1 NICHD_ CB215524.1 –0.422 0.047 –1.76 3.39
06y1 HS_Ut1 cDNA clone 
NICHD_ IMAGE:5936938 5′
HS_Ut1
PCNXL2b pecanex-like 2 (Drosophila) NM_014801.2 –0.773 0.023 –1.75 3.36
CFB complement factor B NM_001710.3 –0.678 0.027 –1.74 3.34
DDIT4b DNA-damage-inducible transcript 4 NM_019058.1 –0.564 0.022 –1.71 3.28
RARRES3b retinoic acid receptor responder NM_004585.2 –0.773 0.022 –1.64 3.12
(tazarotene induced) 3
ZC3H12A zinc finger CCCH-type containing 12A NM_025079.1 –0.499 0.047 –1.62 3.08
PIK3C2Bc phosphoinositide-3-kinase, class 2, NM_002646.2 –0.903 0.004 –1.54 2.91
β polypeptide 
TP53I11 tumor protein p53 inducible protein 11 BC045666.1 –0.702 0.026 –1.48 2.79
GBP2 guanylate binding protein 2, NM_004120.3 –0.689 0.031 –1.43 2.69
interferon-inducible 
ChGnc chondroitin beta1,4 N-acetylgalactos- NM_018371.3 –0.819 0.015 –1.42 2.68
aminyltransferase
ZNF385b zinc finger protein 385 NM_015481.1 –0.955 0.011 –1.38 2.61
UI-E-CQ1- UI-E-CQ1-aew-i-06-0-UIr1 UI-E-CQ1 BM695626.1 –0.661 0.042 –1.37 2.59
aew-i-06- cDNA clone UI-E-CQ1-aew-i-06-0-UI 5′
0-UIr1 UI-
E-CQ1
PDGFRA platelet-derived growth factor receptor, NM_006206.2 –0.653 0.045 –1.34 2.53
α polypeptide
LRRC17b leucine rich repeat containing 17 NM_005824.1 –0.643 0.039 –1.25 2.38
yr27d04r1 yr27d04r1 Soares fetal liver spleen H59349.1 –0.708 0.039 –1.25 2.38
1NFLS cDNA clone IMAGE:206503 5′
MGC:71335b cDNA clone MGC:71335 IMAGE:6088873 BC067086.1 –0.825 0.009 –1.25 2.37
FLJ43880c cDNA FLJ43880 fis, clone TESTI4009022 AK125868.1 –0.796 0.017 –1.24 2.36
ADAM33 ADAM metallopeptidase domain 33 NM_153202.1 –0.709 0.027 –1.22 2.33
RC6-HT0840- RC6-HT0840-150800-022-D11 HT0840 BE719128.1 –0.678 0.031 –1.22 2.33
150800- Homo sapiens cDNA
022-D11
HT0840
FXYD1 FXYD domain containing ion transport NM_021902.2 –0.578 0.044 –1.20 2.29
regulator 1 (phospholemman) 
MAF v-maf musculoaponeurotic NM_005360.2 –0.568 0.044 –1.19 2.29
fibrosarcoma oncogene homolog 
(avian)
Continued
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ABI3BPc ABI gene family, member 3 (NESH) NM_015429.2 –0.705 0.012 –1.17 2.26
binding protein 
UI-E-DW1- UI-E-DW1-ahc-b-11-0-UIr1 UI-E-DW1 BM712072.1 –0.854 0.008 –1.14 2.21
ahc-b-11- cDNA clone UI-E-DW1-ahc-b-
0-UIr1 UI-E 11-0-UI 5′
-DW1c
MTSS1b metastasis suppressor 1 NM_014751.2 –0.731 0.009 –1.14 2.20
CLDN15b claudin 15 NM_014343.1 –0.714 0.022 –1.13 2.19
GANAB glucosidase, alpha; neutral AB NM_198334.1 –0.719 0.020 –1.13 2.19
C1QTNF1c C1q and tumor necrosis factor related NM_030968.2 –0.672 0.017 –1.13 2.18
protein 1 
ATF3 activating transcription factor 3 NM_004024.2 –0.619 0.049 –1.10 2.14
C17orf58c chromosome 17 open reading frame 58 NM_181655.1 –0.813 0.007 –1.10 2.14
P2RY6c pyrimidinergic receptor P2Y, G-protein NM_004154.3 –0.814 0.021 –1.08 2.12
coupled, 6 
ADAM8c a disintegrin and metalloproteinase  NM_001109.1 –0.628 0.044 –1.06 2.08
domain 8
PNRC1 proline-rich nuclear receptor  NM_006813.1 –0.902 0.008 –1.05 2.07
coactivator 1
FLJ23438b cDNA: FLJ23438 fis, clone HRC13275 AK027091.1 –0.738 0.016 –1.04 2.06
BTN3A3c butyrophilin, subfamily 3, member A3 NM_197974.1 –0.833 0.009 –1.03 2.05
UI-H-EU0-azp- UI-H-EU0-azp-a-24-0-UIs1 NCI_CGAP_ BQ181011.1 –0.716 0.009 –1.01 2.01
a-24-0-UIs1 Car1 cDNA clone IMAGE: 5851679 3′
NCI_
CGAP_
Car1b
CREB5b cAMP responsive element binding NM_004904.1 –0.9 0.010 –1.00 2.00
protein 5
HLA-G HLA-G histocompatibility antigen,  NM_002127.3 –0.721 0.028 –0.99 1.99
class I, G
MATN2 matrilin 2 NM_030583.1 –0.743 0.027 –0.96 1.95
HHLA2 HERV-H LTR-associating 2 NM_007072.2 –0.488 0.024 –0.95 1.93
HLA-F major histocompatibility complex, NM_018950.1 –0.619 0.039 –0.95 1.93
class I, F 
TXNIP thioredoxin interacting protein NM_006472.1 –0.604 0.034 –0.94 1.92
KLF11 Kruppel-like factor 11 NM_003597.4 –0.493 0.039 –0.92 1.89
ARID5A AT rich interactive domain 5A (MRF1-like) NM_006673.2 –0.526 0.042 –0.92 1.89
PERP PERP, TP53 apoptosis effector NM_022121.2 –0.602 0.042 –0.92 1.89
HHLA1 HERV-H LTR-associating 1 NM_005712.1 –0.661 0.031 –0.92 1.89
GYPCb glycophorin C (Gerbich blood group) NM_002101.3 –0.578 0.046 –0.91 1.88
NUCB1 nucleobindin 1 NM_006184.3 –0.618 0.026 –0.89 1.86
LGALS3BPb lectin, galactoside-binding, soluble, NM_005567.2 –0.784 0.014 –0.89 1.85
3 binding protein 
FLJ20099b cDNA FLJ20099 fis, clone COL04544 AK000106.1 –0.711 0.023 –0.89 1.85
TMEM142Cb transmembrane protein 142C NM_152288.1 –0.803 0.011 –0.87 1.83
ATXN2L ataxin 2-like NM_007245.2 –0.596 0.046 –0.87 1.83
PAQR6b progestin and adipoQ receptor family NM_024897.2 –0.63 0.040 –0.87 1.83
member VI
SPTBN1 spectrin, beta, non-erythrocytic NM_003128.1 –0.62 0.049 –0.87 1.83
1 (SPTBN1)
MGC15875b hypothetical protein MGC15875 NM_032921.1 –0.894 0.013 –0.86 1.81
(MGC15875)
MAPK8IP1 mitogen-activated protein kinase NM_005456.2 –0.642 0.037 –0.86 1.81
8 interacting protein 1 
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ANKZF1 ankyrin repeat and zinc finger domain NM_018089.1 –0.673 0.036 –0.85 1.81
containing 1
CCBE1 collagen and calcium binding EGF NM_133459.1 –0.602 0.034 –0.85 1.81
domains 1
DKFZp779O mRNA; cDNA DKFZp779O1626 (from BX648538.1 –0.676 0.027 –0.83 1.78
1626 clone DKFZp779O1626)
CA12 carbonic anhydrase XII AK000158.1 –0.612 0.040 –0.83 1.78
NFIL3b nuclear factor, interleukin 3 regulated NM_005384.1 –0.803 0.012 –0.83 1.77
IFITM3 interferon induced transmembrane NM_021034.1 –0.604 0.033 –0.83 1.77
protein 3 (1-8U)
SLC27A1 solute carrier family 27 (fatty acid NM_198580.1 –0.621 0.047 –0.81 1.75
transporter), member 1
LAMP1 lysosomal-associated membrane NM_005561.2 –0.648 0.037 –0.80 1.74
protein 1
BCL3 B-cell CLL/lymphoma 3 NM_005178.2 –0.671 0.039 –0.79 1.73
R15896 ya R15896 ya47b07.r1 Soares infant brain R15896.1 –0.645 0.037 –0.79 1.73
47b07.r1 1NIB cDNA clone IMAGE:53125 5′
similar to SP:S37009 S37009 
TRANSPOSASE - ALMOND ;
ZFP64b zinc finger protein 64 homolog (mouse) NM_018197.2 –0.795 0.017 –0.78 1.72
SWAP-70b SWAP-70 protein AB014540.1 –0.708 0.028 –0.77 1.71
P2RX4 purinergic receptor P2X, ligand-gated NM_002560.2 –0.69 0.032 –0.77 1.71
ion channel, 4 
BMP1 bone morphogenetic protein 1 (BMP1) NM_006129.2 –0.598 0.048 –0.76 1.69
SLC25A37 solute carrier family 25, member 37 NM_016612.1 –0.607 0.039 –0.75 1.68
NUB1b negative regulator of ubiquitin-like NM_016118.3 –0.68 0.011 –0.75 1.68
proteins 1 
ACADS acyl-Coenzyme A dehydrogenase, NM_000017.1 –0.669 0.046 –0.74 1.67
C-2 to C-3 short chain 
RELB v-rel reticuloendotheliosis viral NM_006509.2 –0.682 0.033 –0.74 1.67
oncogene homolog B, nuclear 
factor of kappa light polypeptide 
gene enhancer in B-cells 3 (avian)
PPARAb peroxisome proliferative activated NM_032644.1 –0.753 0.009 –0.74 1.67
receptor, α
ELL3b elongation factor RNA polymerase NM_025165.1 –0.791 0.006 –0.74 1.67
II-like 3 
BCL6c B-cell CLL/lymphoma 6 (zinc finger NM_001706.2 –0.819 0.013 –0.74 1.67
protein 51)
PYGLc phosphorylase, glycogen; liver (Hers NM_002863.2 –0.804 0.016 –0.74 1.67
disease, glycogen storage disease 
type VI)
cDNA clone fs01a03y1 Human Lens cDNA CD673362.1 –0.615 0.030 –0.73 1.66
fs01a03 5′ (Normalized): fs cDNA clone 
fs01a03 5′
602156641F1 602156641F1 NIH_MGC_83 cDNA clone BF681513.1 –0.597 0.037 –0.73 1.66
NIH_MGC IMAGE:4297258 5′
_83
CSNK2A1 casein kinase 2, α 1 polypeptide NM_177560.2 –0.693 0.030 –0.73 1.66
KIAA0082 KIAA0082 NM_015050.1 –0.945 0.010 –0.72 1.65
UI-E-DW0- UI-E-DW0-agh-c-03-0-UIr1 UI-E-DW0 BM706230.1 –0.714 0.024 –0.72 1.65
agh-c-03- cDNA clone UI-E-DW0-agh-c-03-
0-UIr1 UI- 0-UI 5′
E-DW0c
CNTNAP1 contactin associated protein 1 NM_003632.1 –0.628 0.041 –0.72 1.64
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SYNGR1b synaptogyrin 1 NM_004711.3 –0.635 0.043 –0.71 1.64
ING4 inhibitor of growth family, member 4 NM_198287.1 –0.586 0.044 –0.69 1.62
RBM5b RNA binding motif protein 5 NM_005778.1 –0.71 0.024 –0.69 1.61
FLJ34274 cDNA FLJ34274 fis, clone FEBRA2003327 AK091593.1 –0.618 0.044 –0.68 1.60
FAM113Ab family with sequence similarity 113, NM_022760.3 –0.796 0.015 –0.68 1.60
member A
MAP3K6 mitogen-activated protein kinase NM_004672.3 –0.584 0.041 –0.67 1.59
kinase kinase 6
FLJ14360 hypothetical protein FLJ14360 NM_032775.2 –0.638 0.030 –0.67 1.59
B4GALT7b xylosylprotein β 1,4-galactosyltransferase, NM_007255.1 –0.76 0.026 –0.66 1.57
polypeptide 7 (galactosyltransferase I)
CASP7b caspase 7, apoptosis-related cysteine NM_001227.2 –0.637 0.023 –0.65 1.57
peptidase 
IXLb intersex-like (Drosophila) AL137304.1 –0.662 0.031 –0.65 1.57
RHBDF2 rhomboid-like protein 6 NM_024599.2 –0.636 0.030 –0.65 1.57
UCN urocortin NM_003353.2 –0.625 0.044 –0.65 1.57
FLRT2 fibronectin leucine rich transmembrane NM_013231.3 –0.595 0.042 –0.64 1.56
protein 2
FLJ45129 cDNA FLJ45129 fis, clone BRAWH3037394 AK127072.1 –0.582 0.048 –0.63 1.55
LKAPc limkain b1 NM_014647.1 –0.693 0.012 –0.63 1.55
yj34b04r1b yj34b04r1 Soares placenta Nb2HP H02050.1 –0.722 0.017 –0.62 1.54
cDNA clone IMAGE:150607 5′
HECAb headcase homolog (Drosophila) NM_016217.1 –0.629 0.047 –0.62 1.54
BMP1b bone morphogenetic protein 1 NM_006129.2 –0.763 0.024 –0.62 1.54
601194047F1 601194047F1 NIH_MGC_7 cDNA clone BE264943.1 –0.699 0.048 –0.62 1.54
NIH_ IMAGE:3537995 5′
MGC_7
TNIP2b TNFAIP3 interacting protein 2 NM_024309.2 –0.95 0.008 –0.62 1.54
ZNF688 zinc finger protein 688 NM_145271.2 –0.669 0.026 –0.61 1.53
MITF microphthalmia-associated transcription NM_006722.1 –0.62 0.042 –0.60 1.51
factor
FLJ45204b cDNA FLJ45204 fis, clone BRCAN2009168 AK127147.1 –0.807 0.010 –0.60 1.51
UBXD7c UBX domain containing 7 AB018337.1 –0.811 0.007 –0.58 1.50
C16orf48b hypothetical protein DKFZp434A1319 NM_032140.1 –0.714 0.015 –0.58 1.50
(DKFZP434A1319)
ZFHX4 zinc finger homeodomain 4 NM_024721.2 –0.643 0.030 –0.58 1.49
yo60a08r1 yo60a08r1 Soares breast 3NbHBst cDNA H41942.1 –0.692 0.031 –0.58 1.49
clone IMAGE:182294 5′ similar to 
contains Alu repetitive element; 
contains LTR9 repetitive element
ZNF44 zinc finger protein 44 BC032246.1 –0.614 0.032 –0.57 1.49
SETD5 SET domain containing 5 AB051544.1 –0.6 0.031 –0.57 1.48
RNF103 ring finger protein 103 NM_005667.2 –0.648 0.031 –0.57 1.48
TP53INP1 tumor protein p53 inducible nuclear NM_033285.2 –0.642 0.028 –0.55 1.47
protein 1
yr35b01r1 yr35b01r1 Soares fetal liver spleen 1NFLS H59642.1 –0.631 0.038 –0.55 1.46
Soares cDNA clone IMAGE:207241 5′
fetal liver
spleen
1NFLSb
BBS1 Bardet-Biedl syndrome 1 NM_024649.4 –0.616 0.047 –0.54 1.46
FLJ43900 cDNA FLJ43900 fis, clone TESTI4009973 AK125888.1 –0.669 0.043 –0.54 1.45
ITM2Bb integral membrane protein 2B NM_021999.2 –0.681 0.028 –0.54 1.45
PDE6Gb phosphodiesterase 6G, cGMP-specific, NM_002602.1 –0.87 0.003 –0.53 1.44
rod, gamma
Continued
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FKBP4 FK506 binding protein 4, 59kDa NM_002014.2 –0.697 0.023 –0.53 1.44
CHKB choline kinase β (CHKB) NM_005198.3 –0.593 0.039 –0.52 1.43
FLJ11946b cDNA FLJ11946 fis, clone HEMBB1000709 AK022008.1 –0.922 0.005 –0.50 1.42
wi65f08×1 wi65f08×1 NCI_CGAP_Kid12 cDNA AI763182.1 –0.621 0.044 –0.50 1.42
NCI_ clone IMAGE:2398215 3′
CGAP_
Kid12
NSMAFc neutral sphingomyelinase (N-SMase) NM_003580.2 –0.789 0.015 –0.50 1.41
activation associated factor 
SIX5b sine oculis homeobox homolog 5  NM_175875.3 –0.75 0.017 –0.49 1.40
(Drosophila)
64B2 Human 64B2 Human retina cDNA Tsp509I- W22248.1 –0.684 0.022 –0.48 1.39
retina cleaved sublibrary Homo sapiens 
cDNA cDNA not directional
Tsp509I-
cleaved
sublibraryb
XPC xeroderma pigmentosum, NM_004628.2 –0.644 0.041 –0.48 1.39
complementation group C 
603040523F1 603040523F1 NIH_MGC_115 cDNA clone BI824163.1 –0.708 0.030 –0.48 1.39
NIH_MGC_ IMAGE:5181509 5′
115
DKFZp686 mRNA; cDNA DKFZp686K2137 (from AL833529.1 –0.626 0.037 –0.47 1.38
K2137 clone DKFZp686K2137)
SRRM2 serine/arginine repetitive matrix 2 NM_016333.2 –0.632 0.042 –0.45 1.36
SH3GLB2 SH3-domain GRB2-like endophilin B2 NM_020145.2 –0.662 0.037 –0.45 1.36
yd89d12r1 yd89d12r1 Soares fetal liver spleen T87528.1 –0.592 0.050 –0.43 1.35
Soares 1NFLS cDNA clone IMAGE:115415 5′
fetal liver
spleen
1NFLS
cDNA clone cDNA clone IMAGE:3636922 BC062348.1 –0.598 0.035 –0.43 1.34
IMAGE:
3636922
PTPRA protein tyrosine phosphatase, receptor NM_002836.2 –0.624 0.042 –0.41 1.33
type, A
C20orf111 chromosome 20 open reading frame 111 NM_016470.6 –0.632 0.043 –0.41 1.33
MGAT1b mannosyl (α-1,3-)-glycoprotein β-1,2- NM_002406.2 –0.799 0.019 –0.40 1.32
N-acetylglucosaminyltransferase
ZDHHC3b zinc finger, DHHC domain containing 3 NM_016598.1 –0.634 0.040 –0.32 1.25
cDNA DKFZp mRNA; cDNA DKFZp313K127 (from AL833316.1 –0.74 0.024 –0.31 1.24
313K127b clone DKFZp313K127)
GANAB glucosidase, alpha; neutral AB NM_198334.1 –0.676 0.034 –0.31 1.24
x-fold 
up-
regulated 
in Apert
NUBP2 nucleotide binding protein 2 (MinD NM_012225.1 0.66 0.030 0.23 1.17
homolog, E coli)
AGENCOURT_ AGENCOURT_8454944 NIH_MGC_113 BU899205.1 0.587 0.046 0.28 1.22
8454944 cDNA clone IMAGE:6278846 5′
NIH_MGC_
113
ATP5G1 ATP synthase, H + transporting, NM_005175.1 0.618 0.042 0.28 1.22
mitochondrial F0 complex, subunit 
C1 (subunit 9)
Continued
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AGENCOURT_ AGENCOURT_8073800 NIH_MGC_110 BU147450.1 0.678 0.020 0.32 1.25
8073800 cDNA clone IMAGE:6083397 5′
NIH_MGC_
110b
CIB1b calcium and integrin binding 1 (calmyrin) NM_006384.2 0.665 0.035 0.32 1.25
ARL3 ADP-ribosylation factor-like 3 NM_004311.2 0.633 0.033 0.34 1.27
PSMA2 proteasome (prosome, macropain) NM_002787.3 0.648 0.039 0.36 1.28
subunit, α type, 2
MAGED2b melanoma antigen, family D, 2 NM_014599.4 0.599 0.030 0.36 1.28
CUTA cutA divalent cation tolerance NM_015921.1 0.603 0.044 0.37 1.29
homolog (E. coli) 
CSNK1D casein kinase 1, delta NM_001893.3 0.614 0.042 0.37 1.29
MTCH2 mitochondrial carrier homolog 2 (C NM_014342.2 0.576 0.045 0.38 1.30
elegans) (MTCH2), nuclear gene 
encoding mitochondrial protein
yp83b01s1 yp83b01s1 Soares fetal liver spleen H51256.1 0.597 0.049 0.38 1.30
Soares 1NFLS cDNA clone IMAGE:193993 3′
fetal liver
spleen
1NFLS
MAPRE1 microtubule-associated protein, RP/EB NM_012325.1 0.613 0.045 0.38 1.30
family, member 1
SMARCA4 SWI/SNF related, matrix associated, NM_003072.2 0.658 0.034 0.39 1.31
actin dependent regulator of 
chromatin, subfamily a, member 4
PLA2G12A phospholipase A2, group XIIA NM_030821.3 0.668 0.044 0.39 1.31
METTL2Bb methyltransferase like 2 NM_018396.1 0.753 0.019 0.40 1.32
EEF1B2c eukaryotic translation elongation NM_001959.2 0.879 0.011 0.40 1.32
factor 1 β 2
GABPB2 GA binding protein transcription factor, NM_002041.2 0.664 0.027 0.40 1.32
β subunit 2
ZNF414b zinc finger protein 414 NM_032370.1 0.742 0.029 0.41 1.32
ADCY2b adenylate cyclase 2 (brain) NM_020546.1 0.665 0.028 0.41 1.33
CASP8AP2 CASP8 associated protein 2 NM_012115.2 0.621 0.049 0.41 1.33
TIMP3c TIMP metallopeptidase inhibitor 3 BG104808.1 0.966 0.006 0.42 1.34
EIF4A1 eukaryotic translation initiation factor 4A NM_001416.1 0.585 0.038 0.44 1.35
MUS81b MUS81 endonuclease homolog NM_025128.3 0.662 0.024 0.44 1.35
(S. cerevisiae)
CCDC72 coiled-coil domain containing 72 NM_015933.1 0.694 0.030 0.44 1.36
SNRPD1 small nuclear ribonucleoprotein D1 NM_006938.2 0.619 0.044 0.44 1.36
polypeptide 16kDa
DTYMK deoxythymidylate kinase NM_012145.2 0.64 0.037 0.44 1.36
STX2b syntaxin 2 NM_194356.1 0.745 0.019 0.44 1.36
AARSD1b alanyl-tRNA synthetase domain NM_025267.2 0.786 0.019 0.45 1.37
containing 1
CREB3b cAMP responsive element binding NM_006368.4 0.743 0.023 0.46 1.38
protein 3
COX4NB neighbor of COX4 (NOC4) NM_006067.3 0.593 0.030 0.47 1.38
PDZK6 PDZ domain containing 6 NM_015693.2 0.63 0.038 0.47 1.39
UBE2N ubiquitin-conjugating enzyme E2N NM_003348.3 0.584 0.037 0.48 1.39
(UBC13 homolog, yeast)
PPIH peptidyl prolyl isomerase H NM_006347.3 0.676 0.025 0.48 1.40
SIKE suppressor of IKK epsilon NM_025073.1 0.584 0.048 0.50 1.41
TK1 thymidine kinase 1, soluble NM_003258.1 0.685 0.028 0.50 1.41
Continued
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PAFAH1B3 platelet-activating factor NM_002573.2 0.651 0.037 0.51 1.42
acetylhydrolase, isoform Ib, 
γ subunit 29kDa
SFRS7b splicing factor, arginine/serine-rich 7, NM_006276.36 0.705 0.028 0.52 1.44
35kDa
PSMC5 proteasome (prosome, macropain) NM_002805.4 0.624 0.043 0.53 1.44
26S subunit, ATPase, 5
yr11c06r1 yr11c06r1 Soares fetal liver spleen H57392.1 0.742 0.015 0.53 1.44
Soares 1NFLS cDNA clone IMAGE:204970 5′
fetal liver
spleen
1NFLSb
C15orf29b chromosome 15 open reading frame 29 NM_024713.1 0.793 0.011 0.53 1.44
GFOD2c glucose-fructose oxidoreductase NM_030819.2 0.745 0.019 0.53 1.45
domain containing 2
HN1 hematological and neurological NM_001002032.1 0.683 0.045 0.54 1.46
expressed 1
DKFZp451H129 mRNA; cDNA DKFZp451H129 (from AL833295.1 0.649 0.035 0.54 1.46
clone DKFZp451H129)
CKLFb chemokine-like factor NM_016951.2 0.726 0.021 0.55 1.46
OBFC1 oligonucleotide/oligosaccharide- NM_024928.3 0.688 0.027 0.55 1.46
binding fold containing 1
VAMP4b vesicle-associated membrane protein NM_201994.1 0.744 0.010 0.55 1.46
4, transcript variant 1
RRM1 ribonucleotide reductase M1 polypeptide NM_001033.2 0.612 0.045 0.55 1.46
PSME4b proteasome (prosome, macropain) NM_014614.1 0.736 0.022 0.56 1.47
activator subunit 4
PLK3 polo-like kinase 3 (Drosophila) NM_004073.2 0.642 0.036 0.57 1.48
MRPL35b mitochondrial ribosomal protein L35 NM_016622.2 0.706 0.014 0.57 1.49
DLATb dihydrolipoamide S-acetyltransferase NM_001931.2 0.707 0.019 0.58 1.49
(E2 component of pyruvate 
dehydrogenase complex)
HIP2b huntingtin interacting protein 2 NM_005339.3 0.723 0.017 0.58 1.49
C20orf7 chromosome 20 open reading frame 7 NM_199052.1 0.615 0.041 0.59 1.50
UFD1Lb ubiquitin fusion degradation 1 like (yeast) NM_005659.3 0.616 0.023 0.59 1.51
POP5 processing of precursor 5, ribonuclease NM_015918.3 0.623 0.041 0.59 1.51
P/MRP subunit (S cerevisiae) (POP5)
SLC35B3 solute carrier family 35, member B3 NM_015948.2 0.628 0.037 0.60 1.51
CDKN3 cyclin-dependent kinase inhibitor 3 NM_005192.2 0.613 0.044 0.60 1.52
(CDK2-associated dual specificity 
phosphatase)
LZICb leucine zipper and CTNNBIP1 domain NM_032368.3 0.766 0.019 0.60 1.52
containing
LETM1 leucine zipper-EF-hand containing NM_012318.1 0.589 0.049 0.60 1.52
transmembrane protein 1
RNASEH2Ab ribonuclease H2, subunit A NM_006397.2 0.869 0.011 0.60 1.52
NEDD1 neural precursor cell expressed, NM_152905.2 0.643 0.041 0.62 1.53
developmentally downregulated 1
CEP78 centrosomal protein 78kDa AW962072.1 0.672 0.028 0.63 1.54
UI-H-BI0-aah- UI-H-BI0-aah-e-06-0-UIs1 NCI_CGAP_ AW014009.1 0.597 0.037 0.63 1.55
e-06-0-UIs1 Sub1 cDNA clone IMAGE:2709227 3′
NCI_
CGAP_
Sub1
CKAP2 cytoskeleton associated protein 2 NM_018204.2 0.644 0.037 0.66 1.58
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ACTR3Bb ARP3 actin-related protein 3 homolog NM_020445.1 0.765 0.016 0.67 1.59
B (yeast) 
ELAVL1 ELAV (embryonic lethal, abnormal NM_001419.2 0.635 0.041 0.67 1.59
vision, Drosophila)-like 1 
(Hu antigen R)
POLR3Kb polymerase (RNA) III (DNA directed) NM_016310.2 0.802 0.013 0.69 1.61
polypeptide K
PI4KIIb phosphatidylinositol 4-kinase type II NM_018425.2 0.77 0.014 0.69 1.62
TMEM107b transmembrane protein 107 NM_183065.1 0.739 0.022 0.70 1.62
BCAP29 B-cell receptor-associated protein 29 NM_018844.1 0.644 0.040 0.70 1.63
PRPS1L1b phosphoribosyl pyrophosphate NM_175886.2 0.728 0.022 0.71 1.63
synthetase 1-like 1
MTFMTb mitochondrial methionyl-tRNA NM_139242.2 0.866 0.008 0.72 1.64
formyltransferase 
DDX49 DEAD (Asp-Glu-Ala-Asp) box NM_019070.3 0.61 0.046 0.73 1.66
polypeptide 49
RAD1b RAD1 homolog (S. pombe) NM_002853.2 0.71 0.018 0.73 1.66
CMTM5 CKLF-like MARVEL transmembrane NM_138460.2 0.721 0.019 0.74 1.67
domain containing 5
NEK6b NIMA (never in mitosis gene a)-related NM_014397.3 0.715 0.017 0.74 1.67
kinase 6
K-EST0149992 K-EST0149992 L3SNU475 cDNA clone CB108944.1 0.657 0.015 0.75 1.68
L3SNU475b L3SNU475-29-H12 5′
yx15f01s1 yx15f01s1 Soares melanocyte 2NbHM H99198.1 0.766 0.015 0.76 1.70
Soares cDNA clone IMAGE:261817 3′
melanocyte
2NbHMb
EXOSC9b exosome component 9 NM_005033.1 0.721 0.021 0.76 1.70
UI-E-CI0-aah- UI-E-CI0-aah-e-03-0-UIr1 UI-E-CI0 cDNA BM690376.1 0.659 0.031 0.79 1.73
e-03-0-UIr1 clone UI-E-CI0-aah-e-03-0-UI 5′
UI-E-CI0
PTS 6-pyruvoyltetrahydropterin synthase NM_000317.1 0.597 0.047 0.79 1.73
C14orf143 chromosome 14 open reading frame 143 NM_145231.1 0.629 0.047 0.79 1.73
UBE2T HSPC150 protein similar to ubiquitin- NM_014176.1 0.664 0.029 0.83 1.77
conjugating enzyme
SAE1 SUMO-1 activating enzyme subunit 1 NM_005500.1 0.62 0.049 0.83 1.78
AURKB aurora kinase B NM_004217.1 0.692 0.031 0.84 1.79
ARSJ arylsulfatase family, member J AK027201.1 0.708 0.028 0.85 1.80
RRM2b ribonucleotide reductase M2 polypeptide NM_001034.1 0.781 0.019 0.86 1.81
BCL7A B-cell CLL/lymphoma 7A NM_020993.2 0.652 0.034 0.86 1.82
IVNS1ABP influenza virus NS1A binding protein NM_006469.2 0.66 0.035 0.87 1.82
NCAPG non-SMC condensin I complex, subunit G NM_022346.2 0.689 0.028 0.87 1.83
CENPMc centromere protein M NM_024053.2 0.693 0.006 0.87 1.83
C5orf13 chromosome 5 open reading frame 13 NM_004772.1 0.626 0.042 0.89 1.85
MCM4 MCM4 minichromosome maintenance NM_182746.1 0.65 0.030 0.90 1.87
deficient 4 (S. cerevisiae)
FLJ43294 cDNA FLJ43294 fis, clone MESTC1000042 AK125284.1 0.527 0.049 0.93 1.90
PTPDC1b protein tyrosine phosphatase domain NM_152422.3 0.725 0.027 0.95 1.93
containing 1
LOC90624 hypothetical protein LOC90624 NM_181705.1 0.642 0.026 0.95 1.94
SPAG5b sperm associated antigen 5 NM_006461.2 0.876 0.007 0.98 1.97
CTPS CTP synthase NM_001905.1 0.496 0.046 0.98 1.98
zu70f09r1 zu70f09r1 Soares_testis_NHT cDNA AA400694.1 0.578 0.039 0.99 1.98
Soares_ clone IMAGE:743369 5′
testis_NHT
Continued
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To improve the statistical significance
and identify the most robust markers in
the AS gene expression signature we per-
formed a leave-one-out statistical analy-
sis (detailed in Methods). Out of the 263
genes previously found to be differen-
tially expressed, 120 genes were identi-
fied in at least 50 percent of the “leave-
one-out” datasets, and 25 genes were
present in all “leave-one-out” datasets
(Tables 2 and 3).
Quantitative Real Time PCR Validation
of Microarray Data
Quantitative real-time PCR (qRT-PCR)
was performed to confirm the differen-
tial expression of gene sets identified in
the microarray analysis. We selected for
validation four genes belonging to the
previously mentioned functional cate-
gories: STMN1 and SPAG5 (cell prolifera-
tion), RRM2 (cell proliferation and nu-
cleotide metabolism), and HIP2
(suppression of apoptosis and regulation
of gene expression). In addition, two
other genes were selected with non-
related functions: CENPN (centromere
protein), and EEF1B2 (translation elonga-
tion factor). The above selection was
picked at random to avoid a bias toward
a specific pathway in the validation of
the microarray results. qRT-PCR experi-
ments showed that these six genes were
upregulated in AS cells (Figure 3), cor-
roborating the expression results ob-
tained in the microarray experiments.
FGF2 Treatment
To independently confirm the data
generated by microarray analysis, and to
mimic the increased downstream signal-
ing caused by mutant FGFR2, primary
cultured control periosteal cells were
treated with a high concentration of
FGF2 (the high concentration of FGF2
was used to simulate the phosphoryla-
tion status of mutant FGFR2c). Total
RNA was isolated three, six, and 24 h
after FGF2 addition. qRT-PCR was used
to measure the changes in mRNA levels
of the six genes previously used for ex-
perimental validation of the microarray
data: STMN1, SPAG5, RRM2, HIP2,
CENPN and EEF1B2. We observed that
FGF2 treatment differentially stimulated
the expression of these genes only after
24 h of treatment (Figure 4).
DISCUSSION
Despite the important role played by the
periosteum in normal suture biology, the
contribution of FGFR2 mutant periosteal
cells in AS suture closure is unknown. We
report here, for the first time, a strikingly
higher osteoblast differentiation of het-
erozygous p.Ser252Trp FGFR2 mutant cells
as compared with the same kind of cells
from individuals without this mutation
and normal suture fusion. To delineate
molecular mechanisms underlying this ab-
normal cell behavior, we also present here
a statistically significant difference in gene
TABLE 2—Continued
MND1 meiotic nuclear divisions 1 homolog NM_032117.2 0.674 0.034 1.00 2.00
(S. cerevisiae)
KIAA0101 KIAA0101 gene product NM_014736.3 0.58 0.050 1.02 2.03
ZNF738c zinc finger protein 738 BC034499.1 1.07 0.003 1.03 2.04
EHD4c EH-domain containing 4 NM_139265.2 0.725 0.001 1.04 2.06
MNS1b meiosis-specific nuclear structural 1 NM_018365.1 0.832 0.013 1.06 2.08
ARHGAP11A similar to human GTPase-activating NM_014783.2 0.7 0.027 1.08 2.12
protein
CENPNc centromere protein N NM_018455.3 1.142 0.001 1.10 2.14
STMN1b stathmin 1/oncoprotein 18 NM_203401.1 0.969 0.006 1.11 2.16
DUSP2b dual specificity phosphatase 2 NM_004418.2 0.953 0.004 1.17 2.25
SPBC25b spindle pole body component 25 NM_020675.3 0.892 0.010 1.18 2.27
homolog (S. cerevisiae)
HIST1H4C histone 1, H4c NM_003542.3 0.682 0.033 1.22 2.32
TCF19 transcription factor 19 (SC1) BC033086.1 0.631 0.041 1.23 2.34
CIP29 cytokine induced protein 29 kDa NM_033082.1 0.65 0.040 1.24 2.36
FLJ39342b cDNA FLJ39342 fis, clone OCBBF2018873 AK096661.1 0.776 0.017 1.32 2.50
FLJ23131 cDNA: FLJ23131 fis, clone LNG08502 AK026784.1 0.645 0.039 1.61 3.05
zv03f03r1 zv03f03r1 Soares_NhHMPu_S1 cDNA AA419568.1 0.718 0.041 1.74 3.34
Soares_ clone IMAGE:752573 5′
NhHMPu_
S1
CNN1 calponin 1, basic, smooth muscle NM_001299.3 0.808 0.022 2.09 4.24
HAPLN1c hyaluronan and proteoglycan link NM_001884.2 1.003 0.005 3.00 7.99
protein 1
aSNR stands for “signal to noise ratio”.
bThe 120 genes identified as differentially expressed in at least 50% of the “leave-one-out” datasets. 
cThe 25 genes identified as differentially expressed in 100% of the “leave-one-out” datasets.
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Table 3. 98 genes grouped in functional categories. Transcripts are ordered by their Apert-to-control ratios (Log 2). Upregulated genes in
AS cells are shown in orange. Downregulated genes are shown in blue.
Apert-to- x-fold up- 
Gene control or down-
(Official Accession P Ratio regulated 
Symbol) Gene name number value (Log2) in Apert
Positive regulation of cell proliferation
CIP29 cytokine induced protein 29 kDa NM_033082.1 0.040 1.24 2.36
TCF19 transcription factor 19 (SC1) BC033086.1 0.041 1.23 2.34
SPBC25b spindle pole body component 25 homolog (S. cerevisiae) NM_020675.3 0.010 1.18 2.27
STMN1b stathmin 1/oncoprotein 18 NM_203401.1 0.006 1.11 2.16
SPAG5b sperm associated antigen 5 NM_006461.2 0.007 0.98 1.97
MCM4 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) NM_182746.1 0.030 0.90 1.87
HCAP-G chromosome condensation protein G NM_022346.2 0.028 0.87 1.83
RRM2b ribonucleotide reductase M2 polypeptide NM_001034.1 0.019 0.86 1.81
AURKB aurora kinase B NM_004217.1 0.031 0.84 1.79
NEK6b NIMA (never in mitosis gene a)-related kinase 6 NM_014397.3 0.017 0.74 1.67
CKAP2 cytoskeleton associated protein 2 NM_018204.2 0.037 0.66 1.58
NEDD1 neural precursor cell expressed, developmentally NM_152905.2 0.041 0.62 1.53
downregulated 1
RNASEH2Ab ribonuclease H2, subunit A NM_006397.2 0.011 0.60 1.52
UFD1Lb ubiquitin fusion degradation 1 like (yeast) NM_005659.3 0.023 0.59 1.51
PLK3 polo-like kinase 3 (Drosophila) NM_004073.2 0.036 0.57 1.48
CKLFb chemokine-like factor NM_016951.2 0.021 0.55 1.46
TK1 thymidine kinase 1, soluble NM_003258.1 0.028 0.50 1.41
DTYMK deoxythymidylate kinase NM_012145.2 0.037 0.44 1.36
MUS81b MUS81 endonuclease homolog (S. cerevisiae) NM_025128.3 0.024 0.44 1.35
MAPRE1 microtubule-associated protein, RP/EB family, member 1 NM_012325.1 0.045 0.38 1.30
HECAb headcase homolog (Drosophila) NM_016217.1 0.047 –0.62 1.54
CSNK2A1 casein kinase 2, α 1 polypeptide NM_177560.2 0.030 –0.73 1.66
BCL6a B-cell CLL/lymphoma 6 (zinc finger protein 51) NM_001706.2 0.013 –0.74 1.67
BCL3 B-cell CLL/lymphoma 3 NM_005178.2 0.039 –0.79 1.73
ADAM33 ADAM metallopeptidase domain 33 NM_153202.1 0.027 –1.22 2.33
PDGFRA platelet-derived growth factor receptor, α polypeptide NM_006206.2 0.045 –1.34 2.53
ChGna chondroitin beta1,4 N- NM_018371.3 0.015 –1.42 2.68
acetylgalactosaminyltransferase 
PIK3C2Ba phosphoinositide-3-kinase, class 2, β polypeptide NM_002646.2 0.004 –1.54 2.91
Negative regulation of cell proliferation
RAD1b RAD1 homolog (S. pombe) NM_002853.2 0.018 0.73 1.66
CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual NM_005192.2 0.044 0.60 1.52
specificity phosphatase)
RBM5b RNA binding motif protein 5 NM_005778.1 0.024 –0.69 1.61
ING4 inhibitor of growth family, member 4 NM_198287.1 0.044 –0.69 1.62
IFITM3 interferon induced transmembrane protein 3 (1-8U) NM_021034.1 0.033 –0.83 1.77
KLF11 Kruppel-like factor 11 NM_003597.4 0.039 –0.92 1.89
MTSS1b metastasis suppressor 1 NM_014751.2 0.009 –1.14 2.20
RARRES3b retinoic acid receptor responder (tazarotene induced) 3 NM_004585.2 0.022 –1.64 3.12
Nucleotide metabolism
CTPS CTP synthase NM_001905.1 0.046 0.98 1.98
RRM2b ribonucleotide reductase M2 polypeptide NM_001034.1 0.019 0.86 1.81
PRPS1L1b phosphoribosyl pyrophosphate synthetase 1-like 1 NM_175886.2 0.022 0.71 1.63
POLR3Kb polymerase (RNA) III (DNA directed) polypeptide K NM_016310.2 0.013 0.69 1.61
RRM1 ribonucleotide reductase M1 polypeptide NM_001033.2 0.045 0.55 1.46
TK1 thymidine kinase 1, soluble NM_003258.1 0.028 0.50 1.41
DTYMK deoxythymidylate kinase NM_012145.2 0.037 0.44 1.36
Continued
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TABLE 3—Continued
ADCY2b adenylate cyclase 2 (brain) NM_020546.1 0.028 0.41 1.33
ATP5G1 ATP synthase, H + transporting, mitochondrial F0 complex, NM_005175.1 0.042 0.28 1.22
subunit C1 (subunit 9)
PDE6Gb phosphodiesterase 6G, cGMP-specific, rod, gamma NM_002602.1 0.003 –0.53 1.44
Regulation of gene expression
CIP29 cytokine induced protein 29 kDa NM_033082.1 0.040 1.24 2.36
ZNF738a zinc finger protein 738 BC034499.1 0.003 1.03 2.04
POLR3Kb polymerase (RNA) III (DNA directed) polypeptide K NM_016310.2 0.013 0.69 1.61
ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 NM_001419.2 0.041 0.67 1.59
(Hu antigen R)
HIP2b huntingtin interacting protein 2 NM_005339.3 0.017 0.58 1.49
CREB3b cAMP responsive element binding protein 3 NM_006368.4 0.023 0.46 1.38
CASP8AP2 CASP8 associated protein 2 NM_012115.2 0.049 0.41 1.33
ZNF414b zinc finger protein 414 NM_032370.1 0.029 0.41 1.32
GABPB2 GA binding protein transcription factor, β subunit 2 NM_002041.2 0.027 0.40 1.32
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator NM_003072.2 0.034 0.39 1.31
of chromatin, subfamily a, member 4
SIX5b sine oculis homeobox homolog 5 (Drosophila) NM_175875.3 0.017 –0.49 1.40
ZNF44 zinc finger protein 44 BC032246.1 0.032 –0.57 1.49
ZFHX4 zinc finger homeodomain 4 NM_024721.2 0.030 –0.58 1.49
MITF microphthalmia-associated transcription factor NM_006722.1 0.042 –0.60 1.51
ZNF688 zinc finger protein 688 NM_145271.2 0.026 –0.61 1.53
TNIP2b TNFAIP3 interacting protein 2 NM_024309.2 0.008 –0.62 1.54
ING4 inhibitor of growth family, member 4 NM_198287.1 0.044 –0.69 1.62
BCL6a B-cell CLL/lymphoma 6 (zinc finger protein 51) NM_001706.2 0.013 –0.74 1.67
ELL3b elongation factor RNA polymerase II-like 3 NM_025165.1 0.006 –0.74 1.67
PPARAb peroxisome proliferative activated receptor, α NM_032644.1 0.009 –0.74 1.67
RELB v-rel reticuloendotheliosis viral oncogene homolog B, nuclear NM_006509.2 0.033 –0.74 1.67
factor of kappa light polypeptide gene enhancer in  
B-cells 3 (avian)
ZFP64b zinc finger protein 64 homolog (mouse) NM_018197.2 0.017 –0.78 1.72
BCL3 B-cell CLL/lymphoma 3 NM_005178.2 0.039 –0.79 1.73
NFIL3b nuclear factor, interleukin 3 regulated NM_005384.1 0.012 –0.83 1.77
ANKZF1 ankyrin repeat and zinc finger domain containing 1 NM_018089.1 0.036 –0.85 1.81
ARID5A AT rich interactive domain 5A (MRF1-like) NM_006673.2 0.042 –0.92 1.89
KLF11 Kruppel-like factor 11 NM_003597.4 0.039 –0.92 1.89
CREB5b cAMP responsive element binding protein 5 NM_004904.1 0.010 –1.00 2.00
PNRC1a proline-rich nuclear receptor coactivator 1 NM_006813.1 0.008 –1.05 2.07
ATF3 activating transcription factor 3 NM_004024.2 0.049 –1.10 2.14
MAF v-maf musculoaponeurotic fibrosarcoma oncogene homolog NM_005360.2 0.044 –1.19 2.29
(avian)
ZNF385b zinc finger protein 385 NM_015481.1 0.011 –1.38 2.61
Cell Adhesion
HAPLN1a hyaluronan and proteoglycan link protein 1 NM_001884.2 0.005 3.00 7.99
CIB1b calcium and integrin binding 1 (calmyrin) NM_006384.2 0.035 0.32 1.25
FLRT2 fibronectin leucine rich transmembrane protein 2 NM_013231.3 0.042 –0.64 1.56
CNTNAP1 contactin associated protein 1 NM_003632.1 0.041 –0.72 1.64
CSNK2A1 casein kinase 2, α 1 polypeptide NM_177560.2 0.030 –0.73 1.66
LGALS3BPb lectin, galactoside-binding, soluble, 3 binding protein NM_005567.2 0.014 –0.89 1.85
PERP PERP, TP53 apoptosis effector NM_022121.2 0.042 –0.92 1.89
ADAM8b a disintegrin and metalloproteinase domain 8 NM_001109.1 0.044 –1.06 2.08
CLDN15b claudin 15 NM_014343.1 0.022 –1.13 2.19
ADAM33 ADAM metallopeptidase domain 33 NM_153202.1 0.027 –1.22 2.33
PDGFRA platelet-derived growth factor receptor, α polypeptide NM_006206.2 0.045 –1.34 2.53
Continued
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expression profile of periosteal cells from a
large group of AS patients (p.Ser252Trp
mutation) as compared with normal
FGFR2 expressing cells.
Our study represents the largest sam-
ple where a dominant gain-of-function
mutation of a rare Mendelian disorder is
analyzed through microarray technology.
Successful detection of a gene expression
signature was achieved possibly because
all the patients harbor a common muta-
tion in a tyrosine kinase receptor in-
volved in critical developmental signal-
ing cell pathways that leads to a very
homogeneous phenotype. On the other
hand, our sample size contrasts with the
expression profile studies of complex
disorders, such as cancer, which are etio-
logically very heterogeneous and require
an even larger number of individuals in
the analysis. It will be important to verify
whether other craniosynostotic condi-
tions with either known or unknown
causative mutations are also correlated
with specific gene expression signatures.
Lemonnier et al. (12) reported that AS
p.Ser252Trp mutation induces striking
downregulation of FGFR2 protein in os-
teoblasts, which was attributed to an in-
creased internalization of the receptor. In
contrast, our results indicate that AS pe-
riosteal cells have a different pattern of
FGFR2 expression, as similar FGFR2
transcript and protein levels were ob-
served between control and AS pe-
riosteal cells. These discrepancies may
be due to differences between the two
cell types used in the studies.
Independent confirmation of AS ex-
pression changes identified by our mi-
croarray studies came from three strate-
gies. First we used qRT-PCR to confirm
the upregulation of six genes (STMN1,
SPAG5, RRM2, HIP2, CENPN, EEF1B2) in
AS cell lines. As a second approach, we
used control periosteal cells treated with
high concentrations of exogenous FGF2
(a specific wild type FGFR2c ligand) to
mimic the activation status of mutant
FGFR2. We observed over-expression in
FGF2-treated cells of the six genes previ-
ously confirmed to be upregulated in AS
cells through qRT-PCR. Curiously, we
observed a change in gene expression of
the selected genes only after 24 h of
FGF2 treatment, suggesting that their ex-
pression is a late event of FGFR2c activa-
tion. In addition, these results imply that
the genes differentially expressed in the
AS cells are involved either directly or
TABLE 3—Continued
TNXBb tenascin XB NM_032470.2 0.015 –2.32 4.98
DKFZp434 eEF1A2 binding protein NM_178275.3 0.010 –2.66 6.31
B1231b
Extracellular matrix component, biosynthesis
HAPLN1a hyaluronan and proteoglycan link protein 1 NM_001884.2 0.005 3.00 7.99
TIMP3a TIMP metallopeptidase inhibitor 3 BG104808.1 0.006 0.42 1.34
BMP1b bone morphogenetic protein 1 NM_006129.2 0.024 –0.62 1.54
B4GALT7b xylosylprotein β 1,4-galactosyltransferase, polypeptide 7 NM_007255.1 0.026 –0.66 1.57
(galactosyltransferase I) 
MATN2 matrilin 2 NM_030583.1 0.027 –0.96 1.95
ChGna chondroitin beta1,4 N-acetylgalactosaminyltransferase NM_018371.3 0.015 –1.42 2.68
TNXBb tenascin XB NM_032470.2 0.015 –2.32 4.98
MAPK signaling pathway
DUSP2b dual specificity phosphatase 2 NM_004418.2 0.004 1.17 2.25
STMN1b stathmin 1/oncoprotein 18 NM_203401.1 0.006 1.11 2.16
PLA2G12A phospholipase A2, group XIIA NM_030821.3 0.044 0.39 1.31
PDE6Gb phosphodiesterase 6G, cGMP-specific, rod, gamma NM_002602.1 0.003 –0.53 1.44
TNIP2b TNFAIP3 interacting protein 2 NM_024309.2 0.008 –0.62 1.54
UCN urocortin NM_003353.2 0.044 –0.65 1.57
CASP7b caspase 7, apoptosis-related cysteine peptidase NM_001227.2 0.023 –0.65 1.57
MAP3K6 mitogen-activated protein kinase kinase kinase 6 NM_004672.3 0.041 –0.67 1.59
BCL3 B-cell CLL/lymphoma 3 NM_005178.2 0.039 –0.79 1.73
MAPK8IP1 mitogen-activated protein kinase 8 interacting protein 1 NM_005456.2 0.037 –0.86 1.81
SPTBN1 spectrin, beta, non-erythrocytic 1 (SPTBN1) NM_003128.1 0.049 –0.87 1.83
KLF11 Kruppel-like factor 11 NM_003597.4 0.039 –0.92 1.89
PNRC1a proline-rich nuclear receptor coactivator 1 NM_006813.1 0.008 –1.05 2.07
PDGFRA platelet-derived growth factor receptor, α polypeptide NM_006206.2 0.045 –1.34 2.53
PIK3C2Ba phosphoinositide-3-kinase, class 2, β polypeptide NM_002646.2 0.004 –1.54 2.91
RARRES3b retinoic acid receptor responder (tazarotene induced) 3 NM_004585.2 0.022 –1.64 3.12
aGenes within the list of 120 genes identified as differentially expressed in at least 50 percent of the “leave-one-out” datasets.
bThose within the list of 25 genes identified as differentially expressed in 100 percent of the “leave-one-out” datasets (see Methods for details).
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indirectly with FGFR2c signaling. It is
important to point out that this strategy
replicates the microarray data in a bio-
logically analogous system. Indeed,
Mansukhani et al. (15) showed that
gene expression profiles of a murine
osteoblast cell line harboring the
p.Ser252Trp mutation could be repro-
duced by exogenous FGF treatment.
These findings also suggest that the mu-
tated FGFR2 may over-activate the nor-
mal molecular pathways elicited by wild
type receptor instead of inducing novel
molecular pathways.
As a third approach to validate our
microarray results, we looked at the
differentially expressed transcripts for
genes known to be involved in the
canonical FGFR transduction signaling
pathways. As will be discussed later, we
observed the presence of PIK3C2B gene,
which encodes a protein of the phos-
phoinositide 3-kinase (PI3K) family, and
of several members of the MAPK cas-
cades. One of the important signaling
pathways leading to activation of the
MAP kinases is through FGFR-PI3K
hierarchical cascade. We also observed
different expression profiles concerning
other genes associated with FGFR2 acti-
vation, such as FLRT2, a positive regula-
tor of FGFR cascade, and MITF, a tran-
scription factor acting downstream of
FGFR/MEK/ERK signaling. Therefore,
our results (including both laboratory
and the leave-one-out statistical analy-
sis) support that the expression signa-
ture observed in AS cells do represent a
biological state caused by p.Ser252Trp
mutation in FGFR2.
Analysis of the genes differentially
expressed in AS cells revealed novel
expression networks and cellular
processes possibly involved in AS
pathogenesis. A previous study reported
a gene expression profiling experiment
using fibroblast periosteal cells obtained
from one AS patient (p.Pro253Arg), and
two controls (20). We did not observe
overlap between the list of genes identi-
fied in that study and the set of 263
genes reported here. We think that the
very small number of samples analyzed
in the previous study (one AS patient
and two controls) may have introduced
a considerable bias due to individual
variation in gene expression, which
Figure 3. Real-time PCR showing expression levels for six genes identified as upregulated in AS cells by microarray analysis: STMN1, SPAG5,
RRM2, HIP2, CENPN, and EEF1B2. The expression levels for these genes are enhanced in AS samples when compared with controls.
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would explain the absence of genes in
common in the two studies.
The majority of genes upregulated in
AS cells are associated with positive reg-
ulation of cell proliferation and nu-
cleotide metabolism, suggesting that the
activating FGFR2 mutation induces in-
creased periosteal cell proliferation. In-
deed, an excessive proliferation in AS
cells in comparison to control cells was
clearly evident during tissue culture cell
expansion although further experiments
are needed to confirm this phenotype.
FGFR-MAPK signaling functions as a
trigger of fibroblast cell proliferation.
However, we observed downregulation
of several members of MAPK signaling
cascades (13 out of 16 genes) as well as
PIK3C2B in AS cells. It is of note that
among the three upregulated genes be-
longing to the MAPK cascades is DUSP2,
which is associated with inhibition of
MAPK signaling by dephosphorylating
activated MAPKs. Interestingly, downreg-
ulation of PI3K and MAPK signaling path-
ways have been associated recently with
increased stem cell differentiation (26,27).
Therefore, it is possible that the AS mutant
FGFR2 expressing cells are more commit-
ted toward the osteoblast lineage due to
downregulation of transcripts associated
with PIK3-MAPK signaling networks.
However, further experiments to measure
transcript/protein levels of components of
the PIK3-MAPK pathway in mutant
FGFR2 expressing cells are warranted to
confirm the downregulation and the asso-
ciation of this signaling network with the
pathophysiology of AS.
We also found downregulation of most
of the genes involved in cell adhesion
(11 out of 13 genes) and extracellular ma-
trix composition (five out of seven genes)
in AS cells, which contrast one previous
study that has shown that periosteal AS
cells synthesize a greater amount of ex-
tracellular matrix components (including
glycosaminoglycans, type I and III colla-
gens, and fibronectin) than normal cells
(28). In view of this, it would be interest-
ing to test if the suggested reduction in
Figure 4. Real-time PCR showing expression levels for six genes (STMN1, SPAG5, RRM2, HIP2, CENPN, and EEF1B2) in response to FGF2
treatment. The bars are representing the expression levels of each gene before administration of 0.5 percent FBS and FGF2 (0 h), after 24 h
of administration of 0.5 percent FBS (0.5 percent FBS) and after addition of 0.5 percent FBS and FGF2 (0.5 percent FBS + FGF2).
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cell adhesion and extracellular matrix
complexity of our AS periosteal cells are
associated with the greater osteogenic ca-
pacity of these cells.
As we are aware, the number of signif-
icantly altered genes (263 with a P ≤ 0.05)
does not exceed the expected number of
genes that would be found by chance in
the dataset using the same confidence
interval (476 genes out of 9,526 by
chance alone at P ≤ 0.05, and a one-tailed
distribution). However, if we took into
account the 120 more significant genes
(identified as differentially expressed in
at least 50 percent of the “leave-one-out”
datasets), we did not observe great dif-
ferences in the distribution of the upreg-
ulated and downregulated genes among
the functional categories previously dis-
cussed for the 263 genes. The exception
is the group of genes associated with
apoptosis, in which a tendency of en-
hancement of the number of genes
downregulated in AS cells as compared
with control cells was observed. These
results thus confirm that the most abun-
dant classes of upregulated genes are
those related to positive regulation of
cell proliferation and nucleotide metabo-
lism, whereas the genes associated with
all the other functional categories are
mostly downregulated in AS cells.
It was reported that under osteogenic
differentiation condition, murine calvar-
ial osteoblast cells heterozygous for
p.Ser252Trp mutation in FGFR2 showed
increased apoptosis (13,15,16). However,
we found an inclination toward down-
regulation of genes associated with
apoptosis between control and AS cells
among the 120 genes referred above; in
fact, we did not observe significant cell
death either in control or in the mutant
cell lineages. These discrepancies may
be due to differences in the experimental
models and cell types used in each study.
Taken together, our findings have im-
portant implications in understanding
the periosteum function in the postnatal
pathogenesis of Apert syndrome patients.
The increased proliferative and os-
teogenic potentials here observed in
the AS cells may lead to an expansion of
periosteal cells with the potential to dif-
ferentiate and contribute to premature
suture ossification. It is important to note
that a similar mechanism already has
been discussed for osteoblast cells upon
FGFR over-activation (15). Injuries at the
suture site, as those induced by surgical
repair, could trigger this abnormal pe-
riosteal cell behavior and lead to accelera-
tion of the suture fusion after surgery.
Thus, our results suggest for the first time
that the mutant periosteal cells in AS pa-
tients might play an important role in the
pathogenesis of this disease as well as in
the recurrent suture closure after surgery.
Recently, identification of mutations in
ephrin-B1 gene associated with craniosyn-
ostosis have led to the hypothesis that al-
teration in the cellular pathways activated
by these molecules can lead to an abnor-
mal compartmentalization of the cells
during embryogenesis leading to dis-
turbed tissue boundary formation (29).
Considering the enhanced osteogenic po-
tential of the AS periosteal cells and also
that ephrins recently were shown to acti-
vate FGFRs (30), we would like to suggest
that a similar mechanism may contribute
to the craniosynostosis in FGFR-mutated
patients, once the signals that determine
separate identities of the cranial suture
tissues have been disturbed.
While the full spectrum of molecular
factors that modulate these aberrant
cellular behaviors remains to be deter-
mined, our gene expression profiling
study shall contribute to the identifica-
tion of novel genes with important roles
in ossification of cranial sutures or as
candidates for syndromic craniosynosto-
sis with still unidentified cause. Of par-
ticular note is the recent finding showing
that loss of Dusp6, a member of the DUSP
(dual-specificity phosphatases) family
which is activated by FGFRs and inhibits
MAP Kinases, cause coronal craniosynos-
tosis in mice (31). Therefore DUSP family
members may be considered good candi-
date genes for FGFR-like craniosynosto-
sis. Interestingly, we found that DUSP2 is
one of the most significant differentially
expressed genes in AS periosteal cells. Fi-
nally, the understanding of the molecular
pathways involved in the abnormal AS
periosteum behavior will certainly have
important implications in the prognostic
of surgical repair in syndromic cran-
iosynostosis.
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